October 2024
Pfizer’s HYMPAVZI Receives FDA Approval for Hemophilia A and B Treatment
HYMPAVZI, marstacimab-hncq, hemophilia A, hemophilia B, FDA approval, Pfizer, subcutaneous treatment, anti-TFPI inhibitor
Lilly’s Omvoh Outperforms J&J’s Stelara in Phase III Crohn’s Disease Trial
Omvoh (mirikizumab), Stelara (ustekinumab), Crohn’s disease, Phase III trial, Inflammatory bowel disease (IBD), Eli Lilly, Johnson & Johnson
Mirikizumab Shows Superior Histologic Response in Crohn’s Disease Compared to Ustekinumab
Mirikizumab, Ustekinumab, Crohn’s Disease, Histologic Response, VIVID-1 Trial, Inflammatory Bowel Disease
Transgene Faces Setback with Mid-Stage Failure of Cancer Vaccine Candidate
Transgene, cancer vaccine, mid-stage failure, pipeline setback, oncology research
Eli Lilly Expands Global Footprint with £279 Million Investment in UK’s Biotech Sector
Eli Lilly, Gateway Labs, UK biotech, life sciences, Alzheimer’s treatment, donanemab, investment, healthcare innovation
Lundbeck Strengthens Neuro-Rare Disease Portfolio with $2.6 Billion Acquisition of Longboard Pharmaceuticals
Lundbeck, Longboard Pharmaceuticals, Neuro-Rare Diseases, Acquisition, Biotech, Pharmaceutical Industry
FDA Reconsiders Tirzepatide Shortage Status, Allowing Continued Access to Compounded Versions
FDA, tirzepatide, drug shortage, compounded medications, Eli Lilly, type 2 diabetes, weight loss, GLP-1 medications
Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment
Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical
Eli Lilly Commits £279 Million to UK Life Sciences Sector in Groundbreaking Partnership
Eli Lilly, UK life sciences, £279 million investment, Lilly Gateway Labs, obesity treatment, UK government partnership
Shift Bioscience Secures $16M in Seed Funding to Identify Genes for Epigenetic Clock Reversal
Shift Bioscience, Epigenetic Clock, Anti-Aging Research, Seed Funding, British Startup, Genetic Research